



Pierre Michetti

Contact

Pierre Michetti

Publications (11)

Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. *Digestion* 2020; 101 Suppl 1:16-26.

Schreiner P, Rogler G, Juillerat P, Vavricka S, Vulliemoz M, Restellini S, Schoepfer A, Michetti P, Brand S, Maillard M, Fehr J, Mueller N, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. *J Crohns Colitis* 2020

Sulz M, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F, on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Treatment Algorithms for Crohn's Disease. *Digestion* 2020; 101 Suppl 1:43-57.

Yilmaz B, Stelling J, Wiest R, Swiss IBD Cohort Investigators, Rogler G, Maillard M, Pittet V, Geuking M, Mueller C, Michetti P, Fournier N, Franc Y, Bravo F, Ramon C, Øyås O, Juillerat P, Macpherson A. Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's disease. *Nat Med* 2019; 25:701.

Yilmaz B, Stelling J, Wiest R, Swiss IBD Cohort Investigators, Rogler G, Maillard M, Pittet V, Geuking M, Mueller C, Michetti P, Fournier N, Franc Y, Bravo F, Ramon C, Øyås O, Juillerat P, Macpherson A. Microbial network disturbances in relapsing refractory Crohn's disease. *Nat Med* 2019; 25:323-336.

Pittet V, Michetti P, Mueller C, Braegger C, von Känel R, Schoepfer A, Macpherson A, Rogler G, Swiss IBD Cohort Study Group. Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). *Int J Epidemiol* 2019; 48:385-386f.

Pittet V, Maillard M, Simonson T, Fournier N, Rogler G, Michetti P, Swiss IBD Cohort Study Group(*). Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals. *Clin Gastroenterol Hepatol* 2018; 17:2050-2059.e1.

Vavricka S, Biedermann L, Michetti P, Straumann A, Misselwitz B, Scharl M, Manser C, Greuter T, Zeitz J, Frei P, Borovicka J, Seibold F, Schoepfer A, Rogler G, Spasojevic M. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. *Dig Dis* 2017; 35:423-432.

Vavricka S, Misselwitz B, Scharl M, Heinrich H, Manser C, Safroneeva E, Raja Ali R, Rogler G, Schoepfer A, Greuter T, Zeitz J, Biedermann L, Juillerat P, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. *Inflamm Bowel Dis* 2017

Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Banský G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. *Inflamm Bowel Dis* 2010

Schoepfer A, Straumann A, Seibold F, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Vavricka S, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. *Inflammatory bowel diseases* 2009

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch